Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Chula Vista, California


The purpose of this study is to assess safety and tolerability of AZD1656 after multiple repeated oral doses in patients with type 2 diabetes


Inclusion Criteria: - Male or surgically sterile female of non-childbearing potential (post-menopausal, ie natural or induced menopause with last menstruation >1 year ago and LH and FSH in the post-menopausal range, and/or have undergone hysterectomy and/or bilateral oophorectomy - Diagnosed diabetes Mellitus patients treated with diet and exercise alone or with up to two oral anti-diabetic drugs. Stable glycemic control indicated by no changed treatment within 3 months prior to enrollment - HbA1c ≤10.5 % at screening (HbA1c value according to international DCCT standard) Exclusion Criteria: - Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP - History ischemic heart disease, stroke, transitorisk ischemic attack or symptomatic peripheral vascular disease - Clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results. Positive test of Hepatitis B surface antigen, antibodies to HIV virus and antibodies to Hepatitis C virus



Primary Contact:

Study Director
Klas Malmberg, MD, Phd, Prof
AstraZeneca R&D Mölndal, SE-431 83 Mölndal, Sweden

Backup Contact:


Location Contact:

Chula Vista, California
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.